Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J1VB
|
|||
| Former ID |
DNC010251
|
|||
| Drug Name |
4-(piperazin-1-yl)thieno[3,2-c]pyridine
|
|||
| Synonyms |
106261-27-2; 4-(piperazin-1-yl)thieno[3,2-c]pyridine; 1-{THIENO[3,2-C]PYRIDIN-4-YL}PIPERAZINE; Thieno[3,2-c]pyridine,4-(1-piperazinyl)-; Thieno[3,2-c]pyridine, 4-(1-piperazinyl)-; 4-Piperazin-1-yl-thieno[3,2-c]pyridine; CHEMBL608135; 4-Piperazin-1-ylthieno[3,2-c]pyridine; CHEMBL552833; 4-(1-piperazinyl)thieno[3,2-c]pyridine; 4-piperazine-1-yl-thieno[3,2-c]pyridine; 4-Piperazine-1-yl-thieno[2,3-c]pyridine hydrochloride; ACMC-1BO03; SCHEMBL616087; CTK4A4454; DTXSID10450113; MolPort-002-500-678; RVGRTFBJOXMFAX-UHFFFAOYSA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13N3S
|
|||
| Canonical SMILES |
C1CN(CCN1)C2=NC=CC3=C2C=CS3
|
|||
| InChI |
1S/C11H13N3S/c1-3-13-11(9-2-8-15-10(1)9)14-6-4-12-5-7-14/h1-3,8,12H,4-7H2
|
|||
| InChIKey |
RVGRTFBJOXMFAX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 106261-27-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2C receptor (HTR2C) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.